SCHEMBL30278196

SCHEMBL30278196

FC(F)(F)Oc1ccc2cc[nH]c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.59
POLB P06746 1/20 0.59
MAPK1 P28482 1/20 0.59
KMT2A Q03164 1/20 0.59
AHR P35869 3/20 0.50
KIF11 P52732 1/20 0.47
CMA1 P23946 1/20 0.46
TYR P14679 1/20 0.46
MAOA P21397 1/20 0.44
GHSR Q92847 2/20 0.44
ABL1 P00519 1/20 0.43
BCR P11274 1/20 0.43
KDM4E B2RXH2 2/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
GPR84 Q9NQS5 1/20 0.42
ENPP2 Q13822 2/20 0.42
GPR3 P46089 1/20 0.42
CYP2A6 P11509 1/20 0.42
TRPV1 Q8NER1 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981786 1.00 MEN1 (0.59) MEN1POLBMAPK1KMT2AAHR
SCHEMBL3860188 0.86 GHSR (0.51) MEN1POLBMAPK1KMT2AAHR
SCHEMBL4303440 0.85 KMT2A (0.45) MEN1POLBMAPK1KMT2AAHR
SCHEMBL1196876 0.85 ABL1 (0.52) MEN1POLBMAPK1KMT2AAHR
SCHEMBL7089072 0.82 GHSR (0.54) MEN1POLBMAPK1KMT2AAHR
SCHEMBL3791812 0.81 MEN1 (0.65) MEN1POLBMAPK1KMT2AAHR
SCHEMBL29365896 0.78 MEN1 (0.59) MEN1POLBMAPK1KMT2AAHR
SCHEMBL591242 0.78 MEN1 (0.59) MEN1POLBMAPK1KMT2AAHR
SCHEMBL21145515 0.76 HSD17B10 (0.59) KMT2AKIF11ABL1BCRKDM4E
SCHEMBL3201309 0.76 ABL1 (0.60) AHRGHSRABL1BCRENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034111-A1 NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS CAYMAN CHEMICAL COMPANY INCORPORATED (US) 2026-02-05 US disclosed
WO-2024201248-A1 COMPOUNDS AND METHODS FOR DEGRADING GSPT1 PIN THERAPEUTICS, INC. (KR) 2024-10-03 WO disclosed
EP-4396191-A1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2024-07-10 EP disclosed
WO-2023033740-A1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2023-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034111-A1 NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS PLA2G2F, PLA2R1, PLA2G12A MEN1 3794/4885POLB 1864/4885MAPK1 3473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.